TriSalus Life Sciences, Inc.
Company Stats
- Market Cap
- $265.4M
- as of Sep 30, 2026
- Shares Outstanding
- 61.6M
- Free Float
- 45.9%
Income Statement
- Revenue
- $45.2M
- Operating Income
- -$26.9M
- Net Income
- -$39.2M
- EBITDA
- -$26.3M
- Revenue Growth, 3Y
- 53.9%
- FCF Margin, 3Y Avg
- -152.8%
- FCF Margin, Worst Year
- -276.4%
Cash Flow
- Free Cash Flow
- -$18.9M
- FCF Yield
- -7.1%
- Owner FCF Yield
- -10.6%
Balance Sheet
- Cash & Equivalents
- $20.4M
Returns & Capital
- SBC, 3Y Avg
- $5.3M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $45.2M | -$18.9M | -41.9% |
| FY2024 | $29.4M | -$41.2M | -139.9% |
| FY2023 | $18.5M | -$51.2M | -276.4% |
| FY2022 | $12.4M | -$33.0M | -265.9% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 14, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back